6 results about "Iopromide" patented technology

The invention belongs to the technical field of experiments and the field of anatomical research, and particularly relates to a self-developing vascular casting agent and a preparation method thereof. The invention discloses a preparation method of a self-developing vascular casting agent. The self-developing vascular casting agent is obtained by uniformly mixing iopromide, natural latex, II-type barium sulfate and pigment, wherein in parts by weight, the iopromide accounts for 30-40%; 25%-30% of natural latex; 40% of type II barium sulfate; and 5%-10% of pigment. The blood vessel casting agent developed by the invention is excellent in formula flowability (smooth perfusion), does not cause blockage, can avoid reverse osmosis of a capillary microenvironment, and realizes arteriovenous differentiated perfusion; and meanwhile, high-contrast development is realized, and complete coverage of capillary vessels is basically realized. The optimized blood vessel casting agent formula is completely cured (at room temperature) within 24 hours, the shrinkage rate is low, and blood vessel deformation is avoided.

The invention discloses a contrast agent for enhancing an ELCA volume reduction effect, belongs to the field of medical reagents, and particularly relates to a contrast agent, which comprises a heparin-based compound and a contrast agent, the heparin-based compound comprises heparin, and the content of the heparin-based compound in the contrast agent is 2-64 [mu] g / mL. The contrast agent comprises at least one of iopromide and iodixanol. The heparin-based compound further comprises a heparin derivative, the heparin derivative is prepared by oxidizing heparin and then reacting with a derivating agent, and the derivating agent comprises L-alanyl-L-proline methyl ester hydrochloride. The contrast agent provided by the invention can be combined with ELCA for use, enhances the volume reduction effect of ELCA, has a good ablation effect on vascular plaques, and has high shock wave pressure when acting with excimer laser.

The application discloses a contrast agent for enhancing the effect of ELCA volume reduction, and belongs to the field of medical reagents, and particularly relates to a contrast agent which comprises a heparin-based compound and a contrast agent, wherein the heparin-based compound comprises heparin, and the content of the heparin-based compound in the contrast agent is 2-64 mu g / mL. The contrast agent comprises at least one of iopromide and iodixanol. The heparin-based compound further comprises a heparin derivative, and the heparin derivative is prepared by subjecting heparin to oxidation and then to reaction with a derivatizing agent. The derivatizing agent comprises L-alanyl-L-proline methyl ester hydrochloride. The application is a contrast agent which can be combined with ELCA, enhances the effect of ELCA volume reduction, has a good effect on blood vessel plaque erosion, and has high shock wave pressure when combined with excimer laser.

The invention discloses a preparation method of an iopromide impurity D. The method comprises the following steps: step 1, uniformly mixing and stirring iopromide, sodium methoxide and ethylene glycol monomethyl ether, adding a raw material 2, carrying out heat preservation reaction until the reaction is stopped, adding an HCl diethyl ether solution, carrying out reaction until the reaction is stopped, and filtering and drying to obtain an intermediate 1; and 2, uniformly mixing and stirring the intermediate 1, triethylamine and DMF, adding a mixed solution of a raw material 3 and DMF (10ml) until the reaction stops, carrying out reduced pressure distillation on the reaction solution to obtain a concentrated solution, and purifying a liquid phase prepared from the concentrated solution to obtain the iopromide impurity D.

The invention discloses a preparation method and application of an external contrast agent, and belongs to the technical field of contrast agents. The preparation method comprises the following steps: preparing a coupling solvent from PEG 600 and PEG 1000, and mixing the coupling solvent with iopromide to prepare the contrast agent for external use. The external contrast agent prepared by the invention is beneficial to a low-density object, can present a clear structure during CT scanning imaging, and is also beneficial to reconstruction of a three-dimensional structure of the low-density object. The external contrast agent is sprayed to the surface of the low-density object, so that the low-density object can be developed under X-rays, imaging of the low-density object is facilitated, and a precise three-dimensional structure of the low-density object is reconstructed.

This invention relates to a method for preparing iodine-based nanocontrast agents. Based on the specific and efficient esterification reaction between fluorinated phenylboronic acid groups and ortho-dihydroxy structures, an amphiphilic block polymer containing fluorinated phenylboronic acid groups is co-crosslinked with water-soluble nonionic polyhydroxy iodine-based contrast agents such as iohexol, iodofol, iodixanol, iopromide, iodomeprazole, iodiphenol, iodpentol, and iotram. No chemical modification of the iodine-based contrast agents is required. The water-soluble nonionic polyhydroxy iodine-based contrast agents can be easily and efficiently nano-sized through the phenylboronic acid esterification crosslinking reaction to obtain iodine-based nanocontrast agents. This invention has the advantages of a simple and controllable preparation process, mild reaction conditions, inexpensive and readily available raw materials, and no toxic byproducts. Furthermore, the prepared iodine-based nanocontrast agents exhibit good dispersion stability and excellent imaging contrast performance. When the concentration of the iodine-based nanocontrast agent reaches 120 mg / mL, the CT value reaches as high as 1150 HU.